Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / Incretin and metabolic peptides

92 In the index

Tesofensine TESO

An experimental weight-loss pill studied in human obesity trials, originally developed for Parkinson's and Alzheimer's disease. Trials showed substantial weight loss, larger than many approved obesity drugs at the time, but it also raised heart rate and blood pressure, which has slowed its path to approval.

Also known as NS2330, tesofensina, BLH9UKX9V1, NS 2330, TESOFENSINUM, RefChem:188318, Tesofensine [INN], A1EA1

Effects Lose fat
Routes Oral
Legal status Unapproved / investigational
WADA Not listed

3D Molecular Structure of C17H23Cl2NO

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Chlorine
  • Nitrogen
  • Oxygen

Chemistry

Formula
C17H23Cl2NO
Molar mass
328.3
CAS
195875-84-4
PubChem CID
11370864
IUPAC name
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
InChIKey
VCVWXKKWDOJNIT-ZOMKSWQUSA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial doses under evaluation
Reported range Phase II trials: 0.25-1 mg/day
Route Oral
Frequency Once daily
Duration Trial durations of up to 6 months so far

An experimental weight-loss compound (originally developed for Parkinson's/Alzheimer's) showing substantial trial weight loss but also raising heart rate and blood pressure; not an approved product, so current supply is unregulated.

Where this comes from Published Phase II clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.